Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) FCF Margin (2016 - 2025)

Historic FCF Margin for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to 34.71%.

  • Karyopharm Therapeutics' FCF Margin rose 496300.0% to 34.71% in Q4 2025 from the same period last year, while for Dec 2025 it was 51.6%, marking a year-over-year increase of 362800.0%. This contributed to the annual value of 51.6% for FY2025, which is 362800.0% up from last year.
  • Karyopharm Therapeutics' FCF Margin amounted to 34.71% in Q4 2025, which was up 496300.0% from 13.3% recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' FCF Margin ranged from a high of 20.01% in Q4 2021 and a low of 246.66% during Q2 2021
  • Moreover, its 5-year median value for FCF Margin was 79.27% (2022), whereas its average is 86.38%.
  • As far as peak fluctuations go, Karyopharm Therapeutics' FCF Margin crashed by -1264300bps in 2021, and later soared by 1580900bps in 2022.
  • Karyopharm Therapeutics' FCF Margin (Quarter) stood at 20.01% in 2021, then crashed by -499bps to 79.94% in 2022, then surged by 31bps to 55.07% in 2023, then plummeted by -53bps to 84.33% in 2024, then soared by 59bps to 34.71% in 2025.
  • Its FCF Margin was 34.71% in Q4 2025, compared to 13.3% in Q3 2025 and 49.29% in Q2 2025.